Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
A. P. Jesus-Nunes, Gustavo C. Leal, Fernanda S. Correia-Melo, Flávia Vieira, Rodrigo P Mello, A. T. Caliman-Fontes, Mariana V F Echegaray, Roberta F. Marback, Lívia N F Guerreiro-Costa, Breno Souza-Marques, Cassio Santos-Lima, Lucca S. Souza, Igor D. Bandeira, Flávio Kapczinski, Acioly L T Lacerda, Lucas C Quarantini
Human Psychopharmacology: Clinical and Experimental February 18, 2022 DOI: 10.1002/hup.2836 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Interventions | Racemic ketamine Esketamine |
| Duration | 24 hours and 7 days after infusion |
| Topics | Depression Esketamine Ketamine |
| Citations | 39 |
| Key findings | Clinical predictors of depressive symptom remission and response were identified 24 hours and 7 days after racemic ketamine and esketamine infusions. |
Abstract
Major depressive disorder (MDD) is a leading cause of disability worldwide and most people do not achieve symptom remission. Treatment‐resistant depression (TRD) is characterized by the failure of at least one adequate trial of a major class of antidepressant, with adequate time and dosage. We aimed to identify clinical predictors of depressive symptom remission and response 24 h and 7 days after racemic ketamine and esketamine infusions.
Comparable studies
Other observational and cohort studies on esketamine for depression, most cited first.
Citations in the library
Cited by 28
- Randomized trial of ketamine masked by surgical anesthesia in patients with depression Nature Mental Health October 19, 2023
- Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis. American Journal of Psychiatry March 1, 2025
- Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING) Psychiatry Research July 29, 2023
- Personalized use of ketamine and esketamine for treatment-resistant depression. Translational Psychiatry November 29, 2024
- Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients medRxiv Preprint Server April 28, 2023
and 23 more in the library
Cites 7
- Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders February 18, 2014
- Intravenous arketamine for treatment-resistant depression: open-label pilot study European Archives of Psychiatry and Clinical Neuroscience February 20, 2020
- Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. Journal of Affective Disorders November 14, 2019
- Clinical Predictors of Ketamine Response in Treatment-Resistant Major Depression The Journal of Clinical Psychiatry May 15, 2014
- Predictors of Response to Ketamine in Treatment Resistant Major Depressive Disorder and Bipolar Disorder International Journal of Environmental Research and Public Health April 17, 2018
and 2 more in the library